EGFR and neoplasm: Ultimately, systemic analysis and, in particular, personalized mathematical models—for example, taking into account the KRAS mutation status or the activation of EGFR variants of a patient—and corresponding simulations (validated, at least in some cases, by the treatment of patient‐related tumor organoid models), could help to customize therapy for each patient, and that is exactly what we expect from precision medicine.